Sharepoint Solutions
PRODUCTS
-
In today’s competitive and capital-constrained cell and gene therapy environment, early decisions around Chemistry, Manufacturing, and Controls (CMC) can make or break a therapy's timeline, cost-efficiency, and eventual approval. Yet many emerging cell therapy companies struggle with CMC strategy until it becomes a bottleneck.
-
With Autodesk InfoWorks WS Pro, engineers can accurately model water distribution systems.
-
The gentleMACS™ Dissociator is a benchtop instrument for the semi-automated dissociation of tissues into single-cell suspensions or thorough homogenates.
-
Help your patients make informed decisions without burying them in paper
With electronic informed consent (eConsent) software, your patients can access consent forms using any device they choose. And because it’s part of TrialKit’s unified platform, both your patients and your study team get a seamless experience.
-
Forming part of 3P innovation’s Discover Range, this early-stage development unit uses two sets of die punches to compress pellets and seal them within a blister strip. Used predominantly for dry powder inhalers (DPIs), the ultra-compact filler fits on your lab benchtop.
WHITE PAPERS AND CASE STUDIES
-
The Impact Of Artificial Intelligence On CQV
AI is revolutionizing CQV in life sciences by automating documentation, enabling real-time monitoring, and driving predictive quality to boost efficiency and compliance across validation processes.
-
Response To FDA Black Box Warning
The FDA has launched an investigation into the risk of T-cell malignancies following CAR-T cell immunotherapies. Review the key points of this announcement concerning the CGT research community.
-
Expert Consulting And MRCT Strategy Rescues Oncology Program
Uncover how this strategic approach yielded significant outcomes, including uncovering missing data through IB review, streamlining dosing timelines, and achieving successful recruitment milestones.
-
Phase 1 Clinical Trial Designs And Strategies
With tailored guidance, sponsors can align their modern model-based and model-assisted design choices to program goals, accelerating progress while safeguarding patients.
-
Organizational Assessment For A Large MedTech Company
Explore an organizational assessment run for a medical technology company specializing in tissue repair and regeneration, and the actionable recommendations provided to facilitate future growth.
-
Advancing Rare Disease Clinical Trials With Point-Of-Need Eye Assessments
During the COVID-19 pandemic, Applied Genetic Technologies Corporation (AGTC) faced significant hurdles in enrolling participants due to travel restrictions and site limitations.
-
Authentic Engagement: Reaching Underserved Lupus Patients
By partnering with the ICLF, see how we were able to gain access to and build trust with influential community leaders and advocates within the African American communities located near study sites.
-
Streamlining Single-Use Assemblies In The Bulk-Fill Step Of Downstream Processing
Single-use (SU) systems and components are growing in demand as they offer minimal contamination risk. Review a standardized SU assembly for bulk-fill processing that aims to improve efficiency.
-
Delivering Value Across Sites With Unified Quality Operations
Standardizing quality processes across 14 sites has enabled faster lead times. Discover how a unified platform reduces complexity, improves compliance, and delivers greater value for customers.
-
Early-Stage Development In Rare Pediatric Oncology
Learn about the strategic approach a biotechnology company utilized to address significant hurdles in launching a Phase 1 clinical trial for a novel therapy targeting a rare pediatric cancer.
-
Manufacturing Transfers: Delivering 140+ Precision Medical Devices Without Missing A Deadline
Go inside a successful manufacturing transfer of over 140 Class-III silicone medical devices and on-time delivery for a top-30 OEM through expert project management and rigorous validation processes.
-
Handling Demanding Active Ingredients Safely And Efficiently
See three flexible Optima fill‑finish and syringe assembly systems to boost performance, accuracy, and scalability, enabling efficient processing of diverse formats and supporting rapid CDMO growth.
NEWS
-
PolyPeptide Strengthens Global Peptide Production With Modular Facility Design Approach9/24/2025
PolyPeptide Group AG (SIX: PPGN), a specialized, global CDMO for peptide-based active pharmaceutical ingredients, today announced the successful delivery and installation of pre-built modules at its Malmö, Sweden facility. This marks a key milestone in the company’s modular expansion project at the site, which aims to double its solid-phase peptide synthesis (SPPS) capacity.
-
Merck To Acquire US Biopharma Company SpringWorks Therapeutics To Accelerate Sustainable Growth Of Healthcare Business4/28/2025
Merck, a leading science and technology company, and SpringWorks Therapeutics, Inc., a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck to acquire SpringWorks.
-
Latvian Scientists Create A Tool For More Efficient Public Procurement Evaluation1/10/2026
Much of public procurement evaluation consists of manual work by experts and specialists. This is time-consuming, since it involves comparing extensive documentation, evaluating compliance with regulatory requirements—like whether there are competition-restricting criteria—and other factors.
-
EPA Approves New WIFIA Loans To Strengthen Drinking Water And Wastewater Infrastructure In Oregon And Washington12/18/2025
Today, U.S. Environmental Protection Agency (EPA) is announcing its approval of three Water Infrastructure Finance and Innovation Act (WIFIA) loans totaling $240M.
-
Diasorin Submits The LIAISON NES Point-Of-Care Molecular Diagnostics System And 4-Plex Respiratory Panel To The FDA For 510(k) Clearance And CLIA Waiver7/2/2025
Diasorin announces the submission of a 510(k) premarket notification and CLIA waiver application to the U.S. Food and Drug Administration (FDA) for its LIAISON NES, a next-generation molecular POC testing platform.